Home research company Roundup of life science and health tech news: cancer care, layoffs, funding, and more.

Roundup of life science and health tech news: cancer care, layoffs, funding, and more.

0
Fred Hutchinson Cancer Research Center is now Fred Hutchinson Cancer Center. (Photo by Fred Hutch/Robert Hood)

Life Sciences Week in the Pacific Northwest ended with an announcement that has been in the works for years: UW and Fred Hutch have deepened their relationship to more closely integrate cancer care and research .

With a bigger umbrella, the Fred Hutchinson Cancer Research Center has a new name: Fred Hutchinson Cancer Center. The deal also involves a restructured relationship with Seattle Children’s.

The new arrangement will better connect the lab and clinic, deepen collaborative relationships and accelerate clinical trials, which will benefit patients, but also has the potential to foster new spin-off companies in Seattle.

And there’s a new Fred Hutch spin-out in town, Affini-T Therapeutics, which recently raised $175 million. In an interview, Fred Hutch researcher Phil Greenberg shared his thoughts with GeekWire on how to work effectively with their new industry partner.

More headlines below, including health tech news about a Seattle startup’s new partnership with Yelp.

– Biotech vet Phil Greenberg talks about his new cancer-fighting startup and the next phase of immunotherapy

Yelp expands restaurant health ratings, with help from Seattle startup

Silverback Therapeutics closes its oncology program and plans to lay off 27% of its workforce

Funding News: Enzyme Design Startup Lands $33M; Addiction Treatment Company Raises $3 Million

Latest drama in Athira: an investor asks for the replacement of the CEO and wants two seats on the board of directors

Philip Greenberg (center) and members of his lab at Fred Hutch. (Fred Hutch Photo)

Here’s more life science news from across the Pacific Northwest and beyond:

  • More than 20 years after the first headlines touting the completion of the human genome, it’s finally done. The “dark” parts of the sequence, its more obscure parts—centromeres, telomeres, names familiar to the faithful—are complete. His repetitive DNA fleet is complete. Geneticist Evan Eichler and other UW researchers have helped lead the effort. The Seattle Institute for Systems Biology also contributed.
  • Amazon Web Services spear a collaboration with Thread Research, based in Raleigh-Durham, North Carolina, to decentralize clinical trials and make them more efficient.
  • Impel NeuropharmaThe commercial launch of its newly approved migraine treatment has been “effective”, the company said in its latest revenue report. The company also recently withdrew $100 million in new funding to move the product forward.
  • Bothell, Washington seagen grows. The company job a 38% increase in product sales over last year, reaching $1.4 billion.
  • AGC Organic Productsalso based in Bothell, is manufacturing equipment for a peanut allergy vaccine. The drugmaker will manufacture the product at its Heidelberg plant with its biotech partner.
  • Fred Hutch researchers Jesse Bloom and Tyler Starr discussed how the COVID-19 virus is likely to evolve in the future, in a comment in the New York Times with their colleagues.
  • Cytodyn, based in Vancouver, Washington, has issues with the FDA (it’s happened before). The agency put clinical grips on two of its clinical trials, for HIV and COVID-19.
  • Village Reach was part of a recent round of donations from Seattle billionaire philanthropist MacKenzie Scott. The Seattle Nonprofit received $20 million to advance its work in providing COVID-19 vaccines and other health services to under-reached communities.
  • Luke Timmerman, a longtime biotech journalist and Seattle adventurer, set off on his last quest: Trekking to Everest Base Camp with a host of life science leaders to raise funds for Fred Hutch.